VIJAY MODUR - 01 Dec 2021 Form 4 Insider Report for Eloxx Pharmaceuticals, Inc.

Role: HEAD OF R&D
Signature: /s/ Sumit Aggarwal, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 01 Dec 2021
Net transactions value: -$46,349
Form type: 4
Filing time: 03 Dec 2021, 16:14:26 UTC
Previous filing: 18 May 2021
Next filing: 27 Jan 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ELOX	Common Stock	Options Exercise	$0	+219,326		$0.000000	219,326	01 Dec 2021	Direct	F1
transaction	ELOX	Common Stock	Tax liability	$46,349	-64,373	-29%	$0.7200	154,953	01 Dec 2021	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ELOX	Restricted Stock Units	Options Exercise	$0	-219,326	-100%	$0.000000^*	0	01 Dec 2021	Common Stock	219,326		Direct	F1, F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The restricted stock units issued to the reporting person on April 1, 2021 have fully vested and settled for shares of the Issuer's common stock.
F2	Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F3	The restricted stock units were issued pursuant to the Issuer's 2018 Equity Incentive Plan.